Article: Fosamax(R) Receives FDA Approval for Use in Men.

WEST POINT, Pa., Oct. 2 /PRNewswire/ --

Merck & Co., Inc. (NYSE: MRK) announced today that the Food and Drug Administration has approved Fosamax(R) (alendronate sodium) 10 mg once daily for treatment to increase bone mass in men with osteoporosis. Fosamax is the first medicine to be indicated for men with osteoporosis.

An estimated 2 million American men already have osteoporosis. It is projected that the number of men with osteoporosis will increase approximately 20 percent by the year 2015 due to the aging population.

"Until now physicians have had few options for men with osteoporosis," said Anastasia Daifotis, M.D., senior director, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!